세계의 소비자 직접(DTC) 유전자 검사 시장 보고서(2025년)
Direct-To-Consumer (DTC) Genetic Testing Global Market Report 2025
상품코드 : 1824523
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 250 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ₩ 6,469,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ₩ 9,350,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ₩ 12,232,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

소비자 직접(DTC) 유전자 검사 시장 규모는 향후 몇 년 동안 급성장할 것으로 예상됩니다. 2029년에는 CAGR 16.0%로 38억 7,000만 달러로 성장할 것입니다. 예측 기간의 성장은 검사 제공 확대, 맞춤형 의료와의 통합, 건강 및 웰니스 산업과의 연계, 유전자 연구 발전, 정부 지원, 규제 등에 기인할 것으로 보입니다. 예측 기간의 주요 동향으로는 검사 제공 및 패널 확대, 소비자 교육 이니셔티브, 규제 준수 및 감독, 유전체 데이터 연구 및 기여, 가격 인하 및 접근성 등이 있습니다.

향후 5년간 16.0%의 성장률 전망은 지난번 전망치보다 0.2% 소폭 하락한 수치입니다. 이 감소는 주로 미국과 다른 국가 간의 관세의 영향에 기인합니다. 관세 인상은 영국과 스위스에서 공급되는 SNP 마이크로어레이 칩과 타액 채취 키트의 가격을 상승시키고, 개인화된 건강 인사이트를 위한 본인 부담금을 악화시켜 미국 소비자들에게 부담을 줄 가능성이 높습니다. 또한, 상호 관세와 무역 긴장과 제한의 증가로 인한 세계 경제와 무역에 대한 악영향으로 인해 그 영향은 더욱 광범위하게 나타날 것으로 보입니다.

유전적 전염을 수반하는 질병 및 장애의 유병률 증가는 향후 소비자 직접(DTC) 유전자 검사 시장의 성장을 촉진할 것으로 예상됩니다. 유전질환은 사람의 DNA 변화(돌연변이)로 인한 질병으로 정의되며, 단일 유전자, 다인자, 염색체 장애를 포함합니다. 소비자 직접 유전자 검사는 다양한 유전성 질환에 대한 인식을 높이고, 개인이 건강 예측을 할 수 있도록 도와주며, 건강, 질병 위험 및 기타 특성에 대한 개인화된 정보를 제공합니다. 이 정보는 질병 위험 감소를 위한 효과적인 건강 및 생활습관 선택에 도움을 줄 수 있습니다. 예를 들어, 미국 국립의학도서관(NLM)은 2023년 4월, 65세 이상 미국인 중 약 670만 명이 유전의 영향을 많이 받는 알츠하이머형 치매(AD)에 걸릴 것으로 예측된다고 보고했습니다. 이 수치는 알츠하이머병을 예방, 지연 또는 치료할 수 있는 의학적 돌파구가 마련되지 않는 한 2060년까지 1,380만 명까지 증가할 수 있습니다. 이처럼 유전적으로 감염되는 질병과 장애의 확산이 소비자 직접(DTC) 유전자 검사 시장의 확대를 부추기고 있습니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 - 거시경제 시나리오 금리, 인플레이션, 지정학, 무역 전쟁과 관세, 코로나와 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별·국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 개요

제31장 기타 주요 기업과 혁신적 기업

제32장 세계의 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병

제34장 최근의 시장 동향

제35장 시장 잠재력이 높은 국가, 전략

제36장 부록

KSM
영문 목차

영문목차

Direct-to-consumer genetic testing involves marketing genetic tests directly to consumers through various media channels such as radio, television, print adverts, and the internet. Customers can purchase these tests through online marketplaces and pharmacies. After acquiring a test kit, clients provide a DNA sample, gaining access to their genetic data without the need for a healthcare professional or health insurance provider. Results are typically accessed via a secure website, app, or a written report.

Direct-to-consumer (DTC) genetic testing encompasses various types, including carrier testing, predictive testing, ancestry and relationship testing, nutrigenomic testing, and other variants. Carrier screening assesses whether a person carries genetic alterations for specific disorders. These tests analyze saliva, urine, and blood samples using technologies such as single nucleotide polymorphism chips, whole genome sequencing, and targeted analysis. DTC genetic testing operates under different business models such as health planning, comprehensive genome tests, medical precision tests, and restricted trait tests. End-users of these tests include laboratories, blood banks, nursing homes, hospitals, imaging centers, home care, cosmetics, and other sectors.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.

The direct-to-consumer (DTC) genetic testing market research report is one of a series of new reports from The Business Research Company that provides direct-to-consumer (DTC) genetic testing market statistics, including direct-to-consumer (DTC) genetic testing industry global market size, regional shares, competitors with a direct-to-consumer (DTC) genetic testing market share, detailed direct-to-consumer (DTC) genetic testing market segments, market trends and opportunities, and any further data you may need to thrive in the direct-to-consumer (DTC) genetic testing industry. This direct-to-consumer (DTC) genetic testing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The direct-to-consumer (dtc) genetic testing market size has grown rapidly in recent years. It will grow from $1.84 billion in 2024 to $2.14 billion in 2025 at a compound annual growth rate (CAGR) of 15.9%. The growth in the historic period can be attributed to curiosity about ancestry and heritage, health and wellness trends, marketing and consumer education, privacy and control over genetic data, affordability and accessibility.

The direct-to-consumer (dtc) genetic testing market size is expected to see rapid growth in the next few years. It will grow to $3.87 billion in 2029 at a compound annual growth rate (CAGR) of 16.0%. The growth in the forecast period can be attributed to expanding test offerings, integration with personalized medicine, collaborations with health and wellness industries, advancements in genetic research, government support and regulations. Major trends in the forecast period include expanding test offerings and panels, educational initiatives for consumers, regulatory compliance and oversight, genomic data research and contributions, price reduction and accessibility.

The forecast of 16.0% growth over the next five years reflects a slight reduction of 0.2% from the previous projection. This reduction is primarily due to the impact of tariffs between the US and other countries. Tariff escalations are likely to burden U.S. consumers by driving up the cost of SNP microarray chips and saliva collection kits sourced from the UK and Switzerland, exacerbating out-of-pocket expenses for personalized health insights. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The increasing prevalence of diseases and disorders with genetic transmission is anticipated to drive the growth of the direct-to-consumer (DTC) genetic testing market in the future. A genetic disorder is defined as an illness resulting from changes (mutations) in a person's DNA, encompassing single-gene, multifactorial, and chromosomal disorders. Direct-to-consumer genetic testing raises awareness of various genetic disorders, aiding individuals in making health predictions and providing personalized information about their health, disease risks, and other traits. This information supports effective health and lifestyle choices aimed at reducing disease risk. For example, in April 2023, the National Library of Medicine (NLM), a US-based medical library, reported that approximately 6.7 million Americans aged 65 and older were projected to be living with Alzheimer's dementia (AD) in 2023, a condition significantly influenced by genetics. This figure could rise to 13.8 million by 2060 unless medical breakthroughs are made to prevent, slow, or cure AD. Thus, the growing prevalence of genetically transmitted diseases and disorders is propelling the expansion of the direct-to-consumer (DTC) genetic testing market.

The anticipated expansion of digital health solutions is set to drive the growth of the direct-to-consumer (DTC) genetic testing market in the foreseeable future. Digital health leverages technology to enhance healthcare, improve patient outcomes, streamline processes, and empower individuals in managing their health. DTC genetic testing plays a pivotal role in this digital health growth by actively engaging consumers, integrating genetic data for personalization, facilitating telehealth services, connecting with wearable devices, and advocating for preventive care. An example of this trend is highlighted in a September 2022 report from the American Medical Association, a US-based professional organization. The report reveals a significant increase in the percentage of physicians who perceive digital health tools as beneficial for patient care, rising from 85% in 2016 to 93% in 2022. Furthermore, the average number of digital health tools utilized by physicians has also witnessed a notable growth, increasing from 2.2 in 2016 to 3.8 in 2022. Consequently, the surge in digital health solutions is a driving force behind the growth of the direct-to-consumer (DTC) genetic testing market.

Major players in the direct-to-consumer (DTC) genetic testing market are placing a strategic emphasis on substantial investments in genetic research to maintain their market positions. These investments serve as crucial financial support for genetic testing companies, enabling them to engage in research initiatives, advance technologies, broaden market outreach, ensure regulatory compliance, and foster innovation. As an illustrative example, in November 2022, Redcliffe Labs, an India-based provider of diagnostic services and laboratories, disclosed its intention to allocate an additional $10 million (approximately Rs 81 crore) for the expansion of its genetic and specialized testing portfolio. This financial commitment aims to further enhance the company's capabilities in genetic testing, encompassing areas such as prenatal, oncology, neurology, nephrology, and pharmacogenomics. Notably, Redcliffe Labs has already invested $6 million in the coverage of genetics and specialized testing, emphasizing a forward-looking approach towards next-generation technologies within the diagnostics sector.

Major players in the direct-to-consumer (DTC) genetic testing market are actively engaging in strategic collaborations to fortify their market positions. These strategic partnerships, particularly in the realm of technology-integrated genetic testing, serve to drive innovation, elevate diagnostic capabilities, expand global outreach, ensure adherence to regulatory standards, and propel advancements in personalized medicine. A case in point is the collaboration between Myriad Genetics, a US-based genomic testing company, and Epic Systems, a US-based software company, announced in June 2022. This collaboration focuses on integrating electronic health records (EHR) with genetic testing processes. By seamlessly incorporating Myriad tests into the Epic platform, healthcare providers can efficiently order and review genetic tests, streamlining the overall testing procedure. The integration is designed to improve patient care by delivering crucial genetic insights directly within the electronic health records (EHR) system. Myriad Genetics' strategic emphasis on technology-enabled tools aligns with its growth strategy, with the ultimate goal of enhancing accessibility and efficiency in genetic testing for both patients and clinicians.

In March 2022, LetsGetChecked, a virtual care company based in the United States, specializing in at-home testing, telehealth services, and pharmacy capabilities, successfully acquired Veritas Genetics for an undisclosed sum. This strategic acquisition positions LetsGetChecked to leverage whole-genome sequencing, enabling the initiation of a comprehensive lifecycle of personalized healthcare. The goal is to offer the market an extensive spectrum of health testing and care options. Veritas Genetics, the acquired company, is a biotechnology firm based in the United States, specializing in personal genomics.

Major companies operating in the direct-to-consumer (DTC) genetic testing market include 23andMe, AncestryDNA, MyHeritage, FamilyTreeDNA, Living DNA, Vitagene, Orig3n, DNAfit, Helix, Color Genomics, Circle DNA, CRI Genetics, MapMyGenome, Invitae Corporation, TellmeGen, Pathway Genomics, Genebase Systems, EasyDNA, Nebula Genomics, Dante Labs, Veritas Genetics, Xcode Life, Genomic Express, Genomelink, Genomind, WellnessFX, LetsGetChecked, iGene, Dnadoc, OneOme

North America was the largest region in the direct-to-consumer (DTC) genetic testing market share in 2024. Asia-Pacific was the second-largest region in the global direct-to-consumer (DTC) genetic testing market. The regions covered in the direct-to-consumer (dtc) genetic testing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the direct-to-consumer (dtc) genetic testing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The direct-to-consumer (DTC) genetic testing market includes revenues earned by entities by offering DTC genetic kits and services straight to end-customers, that are used in querying patients' DNA information. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Direct-To-Consumer (DTC) Genetic Testing Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on direct-to-consumer (dtc) genetic testing market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for direct-to-consumer (dtc) genetic testing ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The direct-to-consumer (dtc) genetic testing market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

Scope

Table of Contents

1. Executive Summary

2. Direct-To-Consumer (DTC) Genetic Testing Market Characteristics

3. Direct-To-Consumer (DTC) Genetic Testing Market Trends And Strategies

4. Direct-To-Consumer (DTC) Genetic Testing Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Direct-To-Consumer (DTC) Genetic Testing Growth Analysis And Strategic Analysis Framework

6. Direct-To-Consumer (DTC) Genetic Testing Market Segmentation

7. Direct-To-Consumer (DTC) Genetic Testing Market Regional And Country Analysis

8. Asia-Pacific Direct-To-Consumer (DTC) Genetic Testing Market

9. China Direct-To-Consumer (DTC) Genetic Testing Market

10. India Direct-To-Consumer (DTC) Genetic Testing Market

11. Japan Direct-To-Consumer (DTC) Genetic Testing Market

12. Australia Direct-To-Consumer (DTC) Genetic Testing Market

13. Indonesia Direct-To-Consumer (DTC) Genetic Testing Market

14. South Korea Direct-To-Consumer (DTC) Genetic Testing Market

15. Western Europe Direct-To-Consumer (DTC) Genetic Testing Market

16. UK Direct-To-Consumer (DTC) Genetic Testing Market

17. Germany Direct-To-Consumer (DTC) Genetic Testing Market

18. France Direct-To-Consumer (DTC) Genetic Testing Market

19. Italy Direct-To-Consumer (DTC) Genetic Testing Market

20. Spain Direct-To-Consumer (DTC) Genetic Testing Market

21. Eastern Europe Direct-To-Consumer (DTC) Genetic Testing Market

22. Russia Direct-To-Consumer (DTC) Genetic Testing Market

23. North America Direct-To-Consumer (DTC) Genetic Testing Market

24. USA Direct-To-Consumer (DTC) Genetic Testing Market

25. Canada Direct-To-Consumer (DTC) Genetic Testing Market

26. South America Direct-To-Consumer (DTC) Genetic Testing Market

27. Brazil Direct-To-Consumer (DTC) Genetic Testing Market

28. Middle East Direct-To-Consumer (DTC) Genetic Testing Market

29. Africa Direct-To-Consumer (DTC) Genetic Testing Market

30. Direct-To-Consumer (DTC) Genetic Testing Market Competitive Landscape And Company Profiles

31. Direct-To-Consumer (DTC) Genetic Testing Market Other Major And Innovative Companies

32. Global Direct-To-Consumer (DTC) Genetic Testing Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Direct-To-Consumer (DTC) Genetic Testing Market

34. Recent Developments In The Direct-To-Consumer (DTC) Genetic Testing Market

35. Direct-To-Consumer (DTC) Genetic Testing Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기